Semaglutide Cuts Cardiovascular Events in Landmark Trial
Top-line results show semaglutide for weight loss (Wegovy) cut cardiovascular events in the 17,000-person SELECT CV outcomes trial, which should reframe the health benefit of this weight loss drug.
Source: medscape.com